Compare NetApp Inc. (NTAP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Pfizer Inc — how do they compare? NetApp Inc. trades at $231.05 (market cap $46.31B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 3.4× NetApp Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Pfizer Inc for 158 Days on average.
| NTAP | PFE | |
|---|---|---|
Market Cap | $46.31B | $159.59B |
Volume | 3,002,392 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $235.84 | $29.02 |
52-Week Low | $94.11 | $23.67 |
Typical Hold Time | 57 Days | 158 Days |
Enterprise Value | $45.27B | $211.09B |
Dividend Yield | 0.88% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $231.05, up 1.14% today, with a bullish technical outlook supported by moving averages and positive earnings beats in recent quarters. The company reported strong profitability with a 70.63% gross margin and 19.19% net margin for 2025, alongside strategic AI partnerships announced at INSIGHT 2026. Revenue growth is projected to reach $7.4B in 2026, though valuation ratios like a P/E of 33.3 suggest a premium.
The stock faces risks from high valuation and competitive pressures, but analyst sentiment is mixed with a consensus price target of $219.30. Upside potential hinges on execution of AI initiatives, while downside risks include market volatility and execution missteps. Institutional ownership trends and recent insider activity should be monitored for confidence.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
